CorMedix agreed to acquire substantially all Heron Therapeutics assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, in a cash and stock transaction. Closing is expected in the first quarter of 2027, subject to stockholder approval, regulatory clearance and other customary conditions.
HRTX · Heron Therapeutics, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full. Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 9, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.
Heron Therapeutics, Inc. agreed on November 8, 2026 to sell substantially all assets to CorMedix Inc. for $145.0 million cash and 14,583,333 CorMedix shares, plus royalties and contingent earn-out payments, subject to stockholder and regulatory approvals.
Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.
On November 8, 2026, Heron Therapeutics agreed to sell substantially all assets to CorMedix for $145.0 million cash, subject to closing-cash and net-working-capital adjustments, plus 14,583,333 CorMedix shares, subject to stockholder approval.
On September 23, 2026, Heron Therapeutics entered a Development and License Agreement with Long Grove, securing exclusive U.S. sales rights for certain products, nonexclusive manufacturing rights, and obligations to pay milestones, royalties and expense reimbursements.